Edgar Filing: CELL THERAPEUTICS INC - Form 4

CELL THER Form 4 April 11, 200	APEUTICS IN 7	١C									
FORM	1								•···- · ·	PPROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							OMB Number:	3235-0287			
Check this if no long	ər								Expires:	January 31, 2005	
subject to Section 10 Form 4 or	51AIE 5.	EMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							Estimated a burden hou	average Irs per	
Form 5									response 0.5		
obligation	18 Section $1'$							of 1935 or Section	n		
may conti <i>See</i> Instru 1(b).	nue.		of the Inv	•	•						
(Print or Type R	esponses)										
MUNDINGER MARY ONEIL Symbol				r Name and Ticker or Trading				5. Relationship of Reporting Person(s) to Issuer			
CEI			CELL T	CELL THERAPEUTICS INC [ctic]				(Check all applicable)			
(Last) (First) (Middle) 3. Date				. Date of Earliest Transaction							
501 ELLIOT	TT AVE W, SU	JITE 400	(Month/Da 04/09/20	-				X_ Director Officer (give below)		b Owner er (specify	
(Street) 4. If Amer			ndment, Date Original hth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
Filed(Mont											
SEATTLE, V	WA 98119								More than One Re		
(City)	(State)	(Zip)	Table	e I - Non-D	erivative S	Securi	ties Ac	quired, Disposed o	of, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction D (Month/Day/Yea	ar) Executio any	emed on Date, if 'Day/Year)	3. Transactio Code (Instr. 8)	4. Securi onAcquirec Disposec (Instr. 3,	l (A) o l of (D))	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
				Code V	Amount		Price	(Instr. 3 and 4)			
Common Stock	04/09/2007			A <u>(1)</u>	2,500	А	\$0	6,650	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactiorDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amou Underlying Secur (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Am or Nu of S
Non-Qualified Stock Option (right to buy)	\$ 1.7	04/09/2007		А	12,000	04/09/2007	04/09/2017	Common Stock	12

Edgar Filing: CELL THERAPEUTICS INC - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
MUNDINGER MARY ONEIL 501 ELLIOTT AVE W, SUITE 400 SEATTLE, WA 98119	Х						
Signatures							
Louis A. Bianco, Attorney-in-fact for Mundinger	04/11/2007						
**Signature of Reporting Per	Date						

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Stock award fully vests one year from date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.